查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1593895

肺癌治療市場：按分子、疾病、癌症類型、治療方法、分佈分類 - 全球預測 2025-2030

Lung Cancer Therapeutics Market by Molecules (Biologics, Small Molecules), Disease (NSCLC, SCLC), Cancer Type, Therapy, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年肺癌治療市值為250.4億美元，預計2024年將達271.2億美元，複合年成長率為8.39%，到2030年將達到440.3億美元。

肺癌治療的範圍包括治療和控制肺癌的多種治療方法，包括化療、免疫治療、標靶治療和放射線治療。這些治療方法的需求源自於肺癌的全球負擔，肺癌仍然是全世界癌症相關死亡的主要原因之一。應用範圍廣泛，包括針對特定基因突變的治療方法、支持術前腫瘤縮小以及加速術後恢復。最終用途範圍主要包括醫院、腫瘤中心以及學術和研究機構。精準醫學的進步極大地影響了市場成長，導致個人化治療計劃和對腫瘤基因組學的了解不斷加深。新藥和聯合治療的核准率不斷提高，以及預期轉向更有效、副作用更少的治療方法，正在出現最新的潛在商機。此外，製藥公司和研究機構之間的合作對於加速藥物開發和市場進入至關重要。然而，治療費用上漲、核准流程冗長、地區間治療可近性差異等限制因素已成為主要挑戰。臨床試驗、病患招募和監管挑戰的複雜性也阻礙了市場的成長。目前，最佳創新領域是液態切片和伴同性診斷的開發，以更好地為患者匹配正確的治療方法，以及透過遺傳和分子研究尋找新標靶。該市場充滿活力、競爭激烈，技術進步迅速，這表明需要持續的研發投資和策略夥伴關係關係。駕馭這一複雜環境的有效策略包括促進創新、透過定價策略最大限度地提高患者的可及性，以及保持敏捷性以快速適應不斷發展的科學和監管發展。

主要市場統計
基準年[2023] 250.4億美元
預測年份 [2024] 271.2億美元
預測年份 [2030] 440.3億美元
複合年成長率（%） 8.39%

市場動態：揭示快速發展的肺癌治療市場的關鍵市場洞察

供需的動態交互作用正在改變肺癌治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球肺癌發生率不斷上升
    • 增強加強健康管理意識
    • 政府不斷加強肺癌治療舉措
  • 市場限制因素
    • 學名藥大量供應
    • 肺癌治療患者的平均壽命縮短
  • 市場機會
    • 增加新治療方法研究和開發的資金
    • 採用免疫療法等先進治療方法
  • 市場挑戰
    • 放射線治療和化療副作用的風險

波特五力：開拓肺癌治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解肺癌治療市場的外部影響

外部宏觀環境因素在塑造肺癌治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解肺癌治療市場的競爭格局

肺癌治療市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣肺癌治療市場供應商的績效評估

FPNV定位矩陣是評估肺癌治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了肺癌治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對肺癌治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球肺癌發生率上升
      • 加強醫療照護的意識不斷增強
      • 加強政府對肺癌治療的努力
    • 抑制因素
      • 學名藥供應充足
      • 接受肺癌治療的患者平均壽命縮短
    • 機會
      • 增加新療法研究和開發的資金
      • 引進免疫療法等先進療法
    • 任務
      • 放療和化療副作用的風險
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 按分子分類的肺癌治療市場

  • 生物製藥
  • 小分子

第7章肺癌治療市場：依疾病分類

  • 非小細胞肺癌
  • SCLC

第8章以癌症類型分類的肺癌治療市場

  • 肺類癌
  • 非小細胞肺癌
  • 小細胞肺癌

第9章肺癌治療市場療法

  • 化療
  • 免疫療法
    • Atezolizumab
    • Durvalumab
    • 納武單抗
    • Pembrolizumab
  • 放射治療
    • 外樑
    • 內樑
    • 系統性的
  • 標靶治療
    • Bevacizumab
    • Dabrafenib/曲美替尼
    • Erlotinib
    • Osimertinib

第10章肺癌治療市場經銷商

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章美洲肺癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區肺癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲肺癌治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-437A5D08AE3F

The Lung Cancer Therapeutics Market was valued at USD 25.04 billion in 2023, expected to reach USD 27.12 billion in 2024, and is projected to grow at a CAGR of 8.39%, to USD 44.03 billion by 2030.

The scope of lung cancer therapeutics encompasses a broad range of interventions designed to treat and manage lung cancer, including chemotherapy, immunotherapy, targeted therapy, and radiation therapy. The necessity for these therapies is driven by the global burden of lung cancer, which remains one of the leading causes of cancer-related deaths worldwide. Applications are diverse, encompassing treatment regimens targeting specific genetic mutations, assisting in reducing tumor size pre-operatively, and enhancing post-operative recovery. End-use scope primarily includes hospitals, oncology centers, and academic and research institutions. Market growth is significantly influenced by advancements in precision medicine and a growing understanding of tumor genomics, leading to personalized treatment plans. Latest potential opportunities emerge from the increased approval rate of novel drugs and combinations, promising a shift towards more effective treatments with reduced side effects. Additionally, collaborations between pharmaceutical companies and research institutions are crucial to accelerating drug development and market entry. However, limitations such as high costs of therapy, prolonged approval processes, and the disparity in treatment accessibility across regions pose significant challenges. Complexities in clinical trials, patient recruitment, and regulatory challenges can also hinder market growth. The best areas for innovation currently lie in the development of liquid biopsies and companion diagnostics to better match patients with suitable therapies, as well as the exploration of new targets through genetic and molecular research. The market is dynamic, highly competitive, and characterized by rapid technological advancements, indicating a need for continuous R&D investment and strategic partnerships. Effective strategies to navigate this complex landscape include fostering innovation, maximizing patient access through pricing strategies, and maintaining agility to rapidly adapt to scientific and regulatory developments.

KEY MARKET STATISTICS
Base Year [2023] USD 25.04 billion
Estimated Year [2024] USD 27.12 billion
Forecast Year [2030] USD 44.03 billion
CAGR (%) 8.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lung Cancer Therapeutics Market

The Lung Cancer Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in prevalence of lung cancer across the globe
    • Growing awareness regarding enhanced health care
    • Rising government initiatives for lung cancer treatment
  • Market Restraints
    • Huge availability of the generic drugs
    • Reduced life expectancy of patients undertaking lung cancer treatment
  • Market Opportunities
    • Increasing funding in the field of research and development of new treatment
    • Adoption of advanced therapy such as immunotherapy
  • Market Challenges
    • Risk of side effects of radiation and chemotherapy

Porter's Five Forces: A Strategic Tool for Navigating the Lung Cancer Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lung Cancer Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lung Cancer Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lung Cancer Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lung Cancer Therapeutics Market

A detailed market share analysis in the Lung Cancer Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lung Cancer Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lung Cancer Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lung Cancer Therapeutics Market

A strategic analysis of the Lung Cancer Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis AG, Pfizer Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Molecules, market is studied across Biologics and Small Molecules.
  • Based on Disease, market is studied across NSCLC and SCLC.
  • Based on Cancer Type, market is studied across Lung Carcinoid Tumor, Non-small Cell Lung Cancer, and Small Cell Lung Cancer.
  • Based on Therapy, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy. The Immunotherapy is further studied across Atezolizumab, Durvalumab, Nivolumab, and Pembrolizumab. The Radiation Therapy is further studied across External Beam, Internal Beam, and Systemic. The Targeted Therapy is further studied across Bevacizumab, Dabrafenib/Trametinib, Erlotinib Hydrochloride, and Osimertinib.
  • Based on Distribution, market is studied across Hospital Pharmacies, Online Phramacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in prevalence of lung cancer across the globe
      • 5.1.1.2. Growing awareness regarding enhanced health care
      • 5.1.1.3. Rising government initiatives for lung cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Huge availability of the generic drugs
      • 5.1.2.2. Reduced life expectancy of patients undertaking lung cancer treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing funding in the field of research and development of new treatment
      • 5.1.3.2. Adoption of advanced therapy such as immunotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Risk of side effects of radiation and chemotherapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lung Cancer Therapeutics Market, by Molecules

  • 6.1. Introduction
  • 6.2. Biologics
  • 6.3. Small Molecules

7. Lung Cancer Therapeutics Market, by Disease

  • 7.1. Introduction
  • 7.2. NSCLC
  • 7.3. SCLC

8. Lung Cancer Therapeutics Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Lung Carcinoid Tumor
  • 8.3. Non-small Cell Lung Cancer
  • 8.4. Small Cell Lung Cancer

9. Lung Cancer Therapeutics Market, by Therapy

  • 9.1. Introduction
  • 9.2. Chemotherapy
  • 9.3. Immunotherapy
    • 9.3.1. Atezolizumab
    • 9.3.2. Durvalumab
    • 9.3.3. Nivolumab
    • 9.3.4. Pembrolizumab
  • 9.4. Radiation Therapy
    • 9.4.1. External Beam
    • 9.4.2. Internal Beam
    • 9.4.3. Systemic
  • 9.5. Targeted Therapy
    • 9.5.1. Bevacizumab
    • 9.5.2. Dabrafenib/Trametinib
    • 9.5.3. Erlotinib Hydrochloride
    • 9.5.4. Osimertinib

10. Lung Cancer Therapeutics Market, by Distribution

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Phramacies
  • 10.4. Retail Pharmacies

11. Americas Lung Cancer Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Lung Cancer Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Lung Cancer Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. Boehringer Ingelheim GmbH
  • 5. Bristol Myers Squibb Company
  • 6. Celgene Corporation
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche AG
  • 9. Genentech, Inc.
  • 10. GlaxoSmithKline PLC
  • 11. Merck KGaA
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. LUNG CANCER THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. LUNG CANCER THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LUNG CANCER THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NSCLC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SCLC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LUNG CARCINOID TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY INTERNAL BEAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DABRAFENIB/TRAMETINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ERLOTINIB HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY OSIMERTINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHRAMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MOLECULES, 2018-2030 (USD MI